盐酸关附甲素抗心律失常研究进展  

Research Progress of Guanfu Base A about Antiarrhythmia

作　　者：杨萌萌[1] 范新荣[2] 蔡琳[2] 

机构地区：[1]泸州医学院研究生院,四川泸州646000 [2]成都市第三人民医院心内科,四川成都610031

出　　处：《心血管病学进展》2013年第5期660-664,共5页Advances in Cardiovascular Diseases

摘　　要：心律失常是临床常见的一组以心脏搏动频率或节律异常为特点的疾病,为心源性猝死重要原因.药物是治疗心律失常的重要手段,但循证医学研究认为抗心律失常药物总有效率仅为30%～60%,而致心律失常比例约为5%～15%.盐酸关附甲素为我国自主研究开发的抗心律失常新药,目前针对该药进行的基础及临床研究均证实盐酸关附甲素可有效且安全地对抗心律失常.现总结现有研究成果,简要介绍该药研究进展及应用情况.Arrhythmia is a group of disease characterized by abnormal heart beat frequency or rhythm, which is an important reason for the sudden cardiac death. Drugs are the important means of treatment of arrhythmia, but evidence-based medical research shows that overall efficiency of antiarrhythmic drugs is only 30% -60%, causing arrhythmia rate of 5% ~ 15%. It is guanfu base A （GFA） that a new antiarrhythmic drugs which is currently carried out for basic and clinical studies. The studies provide evidence that GFA is effective and safe against arrhythmia. This paper summarizes the existing research, a brief introduction and application of drug research.

关 键 词：盐酸关附甲素 心律失常 离子通道 

分 类 号：R541.7[医药卫生—心血管疾病]